Combined Intravitreal Bevacizumab and Grid Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion
- 18 November 2011
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 22 (4) , 607-614
Abstract
Purpose: To evaluate long-term efficacy of intravitreal bevacizumab (IVB) versus combined IVB and macular grid laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Methods: In this prospective study, 18 eyes were randomized into 2 groups according to treatment: Group 1 (9 eyes) underwent IVB at baseline, at month 1, and at month 2; Group 2 (9 eyes) underwent same IVB protocol combined with macular grid laser photocoagulation. Macular edema and visual acuity represented the endpoints of the study. IVB reinjections were performed in both groups if recurrent macular edema was diagnosed. Spectral domain optical coherence tomography examination as well as visual acuity examination were performed during follow-up. Statistical evaluation was performed for a matched-pair analysis. Results: In Group 1, median baseline central retinal thickness (CRT) decreased from 420 μm (95% confidence interval 355.6-484.4) to 323 μm (261.44-384.56) at month 12 (p=0.06); median baseline BCVA improved from 0.7 logMAR (0.54-0.86) to 0.4 logMAR (0.29-0.51) at month 12 (p<0.01). In Group 2, baseline CRT decreased from 386 μm (353.91-418.09) to 238 μm (200.58-275.42) at month 12 (p<0.01); median BCVA improved from 0.6 logMAR (0.45-0.75) to 0.2 logMAR (0.12-0.28) at month 12 (p<0.01). A statistically significant difference (p=0.03) was found regarding the median number of injections (Group 1: 4±1.1; Group 2: 3±0.4). Conclusions: Both treatment modalities appeared effective to control BRVO-induced macular edema. In the combined-treatment Group, we observed a lower number of reinjections during follow-up, suggesting the efficacy of grid laser photocoagulation to reduce the number of intravitreal injections and maintain short- and long-term results of the therapy.Keywords
This publication has 37 references indexed in Scilit:
- Retinal vein thrombosis: pathogenesis and managementJournal of Thrombosis and Haemostasis, 2010
- INTRAVITREAL INJECTION OF BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSIONRetina, 2009
- SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR THE MANAGEMENT OF BRANCH AND HEMIRETINAL VEIN OCCLUSIONRetina, 2009
- Intravitreal bevacizumab (Avastin(R)) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trialBritish Journal of Ophthalmology, 2008
- One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusionGraefe's Archive for Clinical and Experimental Ophthalmology, 2008
- The treatment of branch retinal vein occlusion with bevacizumabCurrent Opinion in Ophthalmology, 2008
- Branch Retinal Vein Occlusion: Pathogenesis, Visual Prognosis, and Treatment ModalitiesCurrent Eye Research, 2008
- Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography studyInternational Ophthalmology, 2007
- Interventions for Branch Retinal Vein OcclusionOphthalmology, 2007
- Argon Laser Photocoagulation for Macular Edema in Branch Vein OcclusionAmerican Journal of Ophthalmology, 1984